Titre :

Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists.

Auteur(s) :

Guitton, Zelie [Auteur]
Terriou, Louis [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lega, Jean-Christophe [Auteur]
Nove-Josserand, Raphaele [Auteur]
Hie, Miguel [Auteur]
Amoura, Zahir [Auteur]
Bussel James, B [Auteur]
Hamidou, Mohamed [Auteur]
Rosenthal, Eric [Auteur]
Lioger, Bertrand [Auteur]
Chauveau, Dominique [Auteur]
Chaminade, Axel [Auteur]
Magy-Bertrand, Nadine [Auteur]
Michel, Marc [Auteur]
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]
Audia, Sylvain [Auteur]
Godeau, Bertrand [Auteur]
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]
Mahevas, Matthieu [Auteur]
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]

Titre de la revue :

Rheumatology

Nom court de la revue :

Rheumatology (Oxford)

Numéro :

57

Pagination :

1432–1438

Date de publication :

2018-08

Mot(s)-clé(s) :

thrombosis events
adverse events
thrombopoietin-receptor agonists
antiphospholipid syndrome
systemic lupus erythematosus
immune thrombocytopenia

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Objectives: The use of thrombopoietin-receptor agonists (TPO-RAs) has increased as a second-line therapy in ITP, but the efficacy and safety of such drugs has not been evaluated in SLE-associated ITP. Methods: This was a ...
Lire la suite >Objectives: The use of thrombopoietin-receptor agonists (TPO-RAs) has increased as a second-line therapy in ITP, but the efficacy and safety of such drugs has not been evaluated in SLE-associated ITP. Methods: This was a multicentre retrospective cohort study from 2009 to 2016. Participating centres (n = 11) were secondary- or tertiary-care hospitals belonging to the French national network for adult ITP. Results: We included 18 patients with SLE-ITP treated with TPO-RAs; 10 (55%) had aPL, 5 (27%) showing definite APS. Except for one patient, all (94%) achieved response with TPO-RAs overall. After a median follow-up of 14.7 months with TPO-RAs, four arterial thrombosis events (including one catastrophic APS) occurred in four patients. Two venous thrombosis events occurred in a patient without APS or aPLs. Conclusion: Our results suggest that aPLs should be systematically screened before TPO-RA initiation in patients with SLE. With aPL positivity, alternative therapy should be discussed (if possible), especially in patients with definite APS or suboptimal adherence to anti-coagulation therapy.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Inserm
Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Équipe(s) de recherche :

Immunity, inflammation and fibrsis in auto and allo-reactivity

Date de dépôt :

2019-03-01T15:24:49Z
2024-01-31T15:15:04Z